NCT02773979 is a Phase 1 clinical trial of Chloroquine in Plasmodium Falciparum Infection, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Who is sponsoring NCT02773979?

NCT02773979 is sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

What drugs are being tested in NCT02773979?

Interventions in NCT02773979: Chloroquine, PfSPZ (NF54) Challenge, Placebo.

What condition does NCT02773979 study?

NCT02773979 studies Plasmodium Falciparum Infection.

Is NCT02773979 still recruiting?

NCT02773979 is currently completed. Last updated 27 December 2019.

Last reviewed 2019-12-27 · How we verify

NCT02773979

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PfSPZ Challenge in Healthy Malaria-Naïve Adults in the United States

Completed Phase 1 Last updated 27 December 2019

What this trial tests

Phase 1 trial testing Chloroquine in Plasmodium Falciparum Infection in 28 participants. Completed in 22 January 2018.

Timeline

12 September 2016

Primary endpoint
22 January 2018

22 January 2018

Quick facts

Lead sponsor	National Institute of Allergy and Infectious Diseases (NIAID)
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	prevention
Enrollment	28
Start date	12 September 2016
Primary completion	22 January 2018
Estimated completion	22 January 2018
Sites	1 location across United States

Drugs / interventions tested

Chloroquine (CHLOROQUINE) — full drug profile →
PfSPZ (NF54) Challenge — full drug profile →
Placebo

Conditions studied

Plasmodium Falciparum Infection — all drugs for Plasmodium Falciparum Infection →

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Who can join

Adults 18 to 45, any sex, with Plasmodium Falciparum Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase I trial of the replication-intact PfSPZ Challenge vaccine given under CQ cover will enroll 28 healthy volunteers to receive PfSPZ or placebo, as well as suppressive doses of chloroquine (CQ)on varying schedules. 10 weeks post 3rd immunization subjects will be subjected to controlled human malarial infection. The primary objective of this study is to evaluate the safety and tolerability of escalating doses of Sanaria PfSPZ Challenge administered by DVI on varying schedules to healthy malaria-naïve adults taking suppressive doses of CQ (PfSPZ-CVac).

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

PfSPZ-CVac efficacy against malaria increases from 0% to 75% when administered in the absence of erythrocyte stage parasitemia: A randomized, placebo-controlled trial with controlled human malaria infection.
Murphy SC, Deye GA, Sim BKL, Galbiati S, et al · · 2021 · cited 51× · PMID 34048504 · DOI 10.1371/journal.ppat.1009594
Sporozoite immunization: innovative translational science to support the fight against malaria.
Richie TL, Church LWP, Murshedkar T, Billingsley PF, et al · · 2023 · cited 44× · PMID 37571809 · DOI 10.1080/14760584.2023.2245890
Immune responses to malaria pre-erythrocytic stages: Implications for vaccine development.
Abuga KM, Jones-Warner W, Hafalla JCR. · · 2021 · cited 14× · PMID 32981095 · DOI 10.1111/pim.12795
<i>Plasmodium</i> 18S Ribosomal RNA Biomarker Clearance After Food and Drug Administration-Approved Antimalarial Treatment in Controlled Human Malaria Infection Trials.
Chavtur C, Staubus WJ, Ho M, Hergott DEB, et al · · 2023 · cited 2× · PMID 37265668 · DOI 10.1093/ofid/ofad202

Verify or expand the search:

Other trials of Chloroquine

Trials testing the same drug.

NCT07352566 — Utilization of a Microdevice for Psoriasis and Atopic Dermatitis · Phase 4 · not yet recruiting
NCT06666491 — An Interventional Study to Compare the Efficacy and Safety of Tafenoquine (TQ) and Primaquine (PQ) When Either Are Taken · Phase 3 · recruiting
NCT04704999 — Southeast Asia Dose Optimization of Tafenoquine · Phase 4 · recruiting
NCT02432417 — The Addition of Chloroquine to Chemoradiation for Glioblastoma, · Phase 2 · withdrawn
NCT05980156 — Comparing Chemoprevention Drugs for School-based Malaria Control · Phase 4 · completed

Other National Institute of Allergy and Infectious Diseases (NIAID) trials

Trials by the same sponsor.

NCT07216794 — Small Trial of Alendronate Impact on the Reservoir of HIV · Phase 2 · not yet recruiting
NCT07215858 — BPL-1357 Against H1N1 Influenza Virus Challenge · Phase 2 · recruiting
NCT06987318 — A Study to Evaluate the Safety and Antiviral Activity of Two Human Monoclonal Antibodies (VRC07-523LS and PGT121.414.LS) · Phase 1 · not yet recruiting
NCT07124559 — A Study of Daily Rifapentine Combined With Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of · Phase 1, PHASE2 · not yet recruiting
NCT07342491 — Dasatinib for HIV-1 Reservoir Reduction · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02773979 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Institute of Allergy and Infectious Diseases (NIAID)
Last refreshed: 27 December 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02773979.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing